Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.4K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.4K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

1.1K
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
1.1K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dry powder inhaler selection in COPD: integrating device design, formulation performance, and patient inspiratory capability.

Expert opinion on drug delivery·2026
Same author

From prototype to national standard: a governance framework for scaling simulation-based bronchoscopy training.

Advances in simulation (London, England)·2026
Same author

Enhancing Surgical Proficiency: The Role of Virtual Reality Simulators in Laparoscopic Skill Transfer.

Polski przeglad chirurgiczny·2026
Same author

VR Simulation-Based vs Traditional Apprenticeship Training in Gynecological Laparoscopy: A Comparative Survey of Residents' Expectations, Skills Acquisition, and Training Structure.

Advances in medical education and practice·2026
Same author

SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial.

Allergy·2025
Same author

Improving Pulmonary Delivery of Budesonide Suspensions Nebulized with Constant-Output Vibrating Mesh Nebulizers by Using Valved Holding Chamber.

Pharmaceutics·2025

Related Experiment Video

Updated: Apr 18, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.6K

[New dry powder inhalers].

Andrzej Emeryk1, Michał Pirożyński

  • 1andrzejemeryk@plusnet.pl.

Pneumonologia I Alergologia Polska
|January 12, 2015
PubMed
Summary
This summary is machine-generated.

The Ellipta™ and NEXThaler® inhalers are modern, flow-independent devices for asthma and COPD treatment. They offer advanced features like dual-compound delivery and extra-fine aerosol for improved patient outcomes.

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.2K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.8K

Related Experiment Videos

Last Updated: Apr 18, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.6K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.2K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.8K

Area of Science:

  • Respiratory Medicine
  • Pharmaceutical Technology
  • Device Engineering

Background:

  • Dry powder inhalers (DPIs) are crucial for delivering medication to patients with respiratory conditions like asthma and COPD.
  • Recent advancements in DPI technology aim to improve drug delivery efficiency and patient adherence.
  • The Ellipta™ and NEXThaler® represent the latest generation of DPIs available on the market.

Purpose of the Study:

  • To compare the features and capabilities of the Ellipta™ and NEXThaler® DPIs.
  • To highlight their advancements in drug delivery for asthma and COPD management.
  • To underscore their significance as modern inhaler technologies.

Main Methods:

  • Comparative analysis of the design and functionality of Ellipta™ and NEXThaler® DPIs.
  • Review of their performance characteristics, including flow independence and aerosol properties.
  • Examination of their approval status and intended use in treating asthma and COPD.

Main Results:

  • Both Ellipta™ and NEXThaler® are flow-independent within the physiological range for asthma and COPD patients.
  • Ellipta™ allows simultaneous delivery of two compounds without co-formulation.
  • NEXThaler® delivers an extra-fine aerosol (< 2 μm MMAD) of a combination product.

Conclusions:

  • Ellipta™ and NEXThaler® are advanced DPIs approved globally for asthma and COPD treatment.
  • These devices offer distinct advantages in drug delivery, including dual-compound capability and ultra-fine aerosol generation.
  • Their modern design and features represent significant progress in inhalation therapy.